Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

Doctors say active monitoring, hormone therapy and newer focal treatments are reshaping care decisions for men.

Adding metastasis-directed therapy (MDT) to standard of care was tied to improvements in several survival endpoints in oligometastatic prostate cancer, a recent analysis suggests.

Prostate cancer has been one of the major areas of research for radioligand therapies. Last year, Novartis officials estimated that the March 28, 2025, FDA approval for Pluvicto in metastatic ...

When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

In a new study published in the journal Nature Genetics, Haolong Li, PhD, a researcher at Fred Hutch Cancer Center, and colleagues developed a way to monitor androgen receptor levels inside living ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that ...

Metastasis-directed therapy for oligometastatic prostate cancer was associated with improved outcomes in a systematic review and meta-analysis.

New data show salvage focal therapy rivals surgery in radiorecurrent prostate cancer while reducing complications. Learn more about the findings.

Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...

Step by step, little by little, we are learning how to act on this new staging information,’ one investigator says.

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.